The AJMC® Ophthalmology compendium is a comprehensive resource for clinical news and expert insights for treatment of disorders of the eye.
April 21st 2025
The complete response letter (CRL) specifies that the current dosage duration of aflibercept is still safe but extending the duration is not approved.
Application of Recent Data in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Managed Care Insights and Strategies
1.5 Credits / Ophthalmology, Optometry
View More
Leveraging Novel Therapies to Transform Demodex Blepharitis Care
May 13, 2025 | 7:00 PM ET
View More
Patient-Centered Treatment Plans for Management of Neovascular (Wet) AMD and Diabetic Macular Edema: Insights on Recent Efficacy, Safety, and Real-World Data to Improve Adhere...
1.5 Credits / Ophthalmology/Optometry
View More
Leveraging Novel Therapies to Transform Demodex Blepharitis Care (6/11)
Jun 11, 2025 1:00 PM ET
View More
Integrating Multi-Cancer Early Detection Tests Into Clinical Practice: The Health Economics Perspective for Managed Care Professionals
1.5 Credits / Oncology
View More
The Evolving Strategies for Managing nAMD and DME: Empowering Managed Care Decisions for Improved Patient Outcomes
1.5 Credits / Endocrinology, Diabetes & Metabolism, Ophthalmology/Optometry
View More
Integrated Health Benefits Plans Gaining Attention
December 2nd 2014Employers and employees are seeing eye-to-eye when it comes to integrated health benefits. Not only do employees see how an integrated plan can improve quality of care and health, but employers see how it makes good business sense.
Read More
Drug Cost Not an Indication of Effectiveness
December 10th 2013In the battle to control costs and out-of-pocket expenses for consumers, it would seem logical that doctors would choose the lower-cost drug. However, a report found that when given the choice, doctors chose the more expensive eye medicine over a lower cost option, even when both prescriptions provided the same effective treatment.
Read More